Pragmatic COPERNICUS Design for Delivering Subcutaneous Amivantamab in Practice

Elizabeth Dennis, MSN, APRN, FNP-C, describes what sets the COPERNICUS study apart from the MARIPOSA trial in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: a focus on treatment implementation, not only efficacy. She explains that COPERNICUS evaluates subcutaneous amivantamab-based regimens in a more pragmatic clinical setting. The study assesses safety and adherence to prophylactic strategies designed to reduce dermatologic toxicities, venous thromboembolism, and administration-related reactions. Ms. Dennis considers this focus important because many patients have comorbidities and real-world challenges that traditional trials may not fully represent. She shares that COPERNICUS is a single-arm study without a randomized comparator and with relatively early follow-up, which limits direct comparisons and long-term conclusions. She views subcutaneous amivantamab as an important first-line addition that supports individualized treatment decisions. “While MARIPOSA established the survival benefit of amivantamab plus lazertinib, the [subcutaneous] formulation may improve treatment delivery,” she says. “COPERNICUS is helping us understand how to safely implement these regimens in our routine practice.”